JK

John Kelly

Atomo Diagnostics Limited | Founder, Chief Executive Officer, Managing Director
Mr Kelly has focused on developing and commercializing innovative healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the Mirage Swift and Activa mask systems.

Company and Roles

Company
Title
Tenure
Since
AT1
AT1
Atomo Diagnostics Limited
  • Founder
  • Chief Executive Officer
  • Managing Director
14yrs, 8mthApr 2010

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
AT1
AT1
Atomo Diagnostics Limited
30/06/2472,490,248N/A666,666N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
AT1
AT1
Atomo Diagnostics Limited
03/08/23
Expiry
666,666$0.030$19,999Options expired
AT1
AT1
Atomo Diagnostics Limited
27/10/22
Issued
666,666$0.020$13,333Issue of options
AT1
AT1
Atomo Diagnostics Limited
25/08/22
Expiry
666,667$0.073$48,666Options expired
AT1
AT1
Atomo Diagnostics Limited
03/11/21
Sell
1,040,000$0.276$286,896As advised by the company
AT1
AT1
Atomo Diagnostics Limited
03/11/21
Issued
333,333$0.265$88,333Issue of options